273 related articles for article (PubMed ID: 3157064)
1. A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptors.
Kaumann AJ; Frenken M
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jan; 328(3):295-300. PubMed ID: 3157064
[TBL] [Abstract][Full Text] [Related]
2. Allosteric properties of 5-HT2 receptors in tracheal smooth muscle.
Lemoine H; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 1986 Jun; 333(2):91-7. PubMed ID: 2944004
[TBL] [Abstract][Full Text] [Related]
3. Allosteric properties of the 5-HT2 receptor system of the rat tail artery. Ritanserin and methysergide are not competitive 5-HT2 receptor antagonists but allosteric modulators.
Frenken M; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 1987 Apr; 335(4):359-66. PubMed ID: 3110629
[TBL] [Abstract][Full Text] [Related]
4. Ketanserin causes surmountable antagonism of 5-hydroxytryptamine-induced contractions of large coronary arteries of dog.
Frenken M; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jan; 328(3):301-3. PubMed ID: 3157065
[TBL] [Abstract][Full Text] [Related]
5. Effects of tryptamine mediated through 2 states of the 5-HT2 receptor in calf coronary artery.
Frenken M; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):484-92. PubMed ID: 3137478
[TBL] [Abstract][Full Text] [Related]
6. Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors.
Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 1983 Jun; 323(2):149-54. PubMed ID: 6136920
[TBL] [Abstract][Full Text] [Related]
7. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors.
Kaumann AJ; Frenken M; Posival H; Brown AM
Circulation; 1994 Sep; 90(3):1141-53. PubMed ID: 8087924
[TBL] [Abstract][Full Text] [Related]
8. Interconversion into a low active state protects vascular 5-HT2-receptors against irreversible antagonism by phenoxybenzamine.
Frenken M; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 1987 May; 335(5):481-90. PubMed ID: 3614385
[TBL] [Abstract][Full Text] [Related]
9. ICI 169,369 is both a competitive antagonist and an allosteric activator of the arterial 5-hydroxytryptamine2 receptor system.
Kaumann AJ; Frenken M
J Pharmacol Exp Ther; 1988 Jun; 245(3):1010-5. PubMed ID: 3385635
[TBL] [Abstract][Full Text] [Related]
10. Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro.
Kemp BK; Cocks TM
Br J Pharmacol; 1995 Oct; 116(4):2183-90. PubMed ID: 8564247
[TBL] [Abstract][Full Text] [Related]
11. Tryptaminergic receptors in the bovine pulmonary vasculature: effects of ketanserin.
Ogunbiyi PO; Eyre P
Res Commun Chem Pathol Pharmacol; 1984 Apr; 44(1):31-55. PubMed ID: 6328601
[TBL] [Abstract][Full Text] [Related]
12. 5-Hydroxytryptamine (5-HT) contracts the guinea-pig isolated iliac artery via 5-HT1-like and 5-HT2 receptors.
Pertz H
Naunyn Schmiedebergs Arch Pharmacol; 1993 Dec; 348(6):558-65. PubMed ID: 8133899
[TBL] [Abstract][Full Text] [Related]
13. Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries.
Ellwood AJ; Curtis MJ
Br J Pharmacol; 1997 Nov; 122(5):875-84. PubMed ID: 9384503
[TBL] [Abstract][Full Text] [Related]
14. Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs.
Nagakura Y; Kamato T; Nishida A; Ito H; Yamano M; Miyata K
Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):489-98. PubMed ID: 8740141
[TBL] [Abstract][Full Text] [Related]
15. A two-state model for the 5-HT2 receptor: effects of alpha-adrenoceptor ligands.
Kaumann AJ
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S88-92. PubMed ID: 2459522
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the response to 5-carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries.
Toda N; Okamura T
J Pharmacol Exp Ther; 1990 May; 253(2):676-82. PubMed ID: 2338652
[TBL] [Abstract][Full Text] [Related]
17. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
Lucki I; Nobler MS; Frazer A
J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
[TBL] [Abstract][Full Text] [Related]
18. 5-hydroxytryptamine antagonistic effects of ICI 169,369, ICI 170,809 and methysergide in human temporal and cerebral arteries.
Jansen I; Blackburn T; Eriksen K; Edvinsson L
Pharmacol Toxicol; 1991 Jan; 68(1):8-13. PubMed ID: 2008418
[TBL] [Abstract][Full Text] [Related]
19. 5-HT1-like receptors requiring functional cyclo-oxygenase and 5-HT2 receptors independent of cyclo-oxygenase mediate contraction of the human umbilical artery.
MacLennan SJ; Whittle MJ; McGrath JC
Br J Pharmacol; 1989 Jul; 97(3):921-33. PubMed ID: 2503229
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation of tachycardia by 5-HT1-like receptors.
Saxena PR; Mylecharane EJ; Heiligers J
Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):121-9. PubMed ID: 2931607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
